Literature DB >> 10806795

Study on the hypercoagulable state in patients with angina and myocardial infarction.

Y Hu1, S Song, W Wei, Z Liu, Y Tu, J Zhang.   

Abstract

The molecular markers of platelet activation, coagulation and fibrinolysis were detected in 60 cases of coronary heart disease (CHD), including 15 cases of stable angina (SA), 21 cases of unstable angina (UA) and 24 cases of acute myocardial infarction (AMI). The results showed that the platelet granule membrane protein 140 (GMP-140) level increased obviously in CHD groups compared with normal control, suggesting that platelet activation existed in CHD. Prothrombin fragment F1 + 2 and fibrinopeptide A (FPA) were examined to observe the activation of coagulation. No difference was found between SA group and normal controls, while their levels in both UA group and AMI group were significantly higher than in normal control and SA group (both P < 0.05). D-D dimer and alpha 2-plasma inhibitor (alpha 2-PI) were detected to observe fibrinolytic state. The results showed that no difference existed between SA group and normal controls, while both D-D dimer and alpha 2-PI in UA group and AMI group were significantly elevated than those in SA group and normal controls (P < 0.05).

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 10806795     DOI: 10.1007/bf02888272

Source DB:  PubMed          Journal:  J Tongji Med Univ        ISSN: 0257-716X


  2 in total

1.  Fibrin formation and platelet aggregation in patients with severe coronary artery disease: relationship with the degree of myocardial ischemia.

Authors:  A Gallino; A Haeberli; H R Baur; P W Straub
Journal:  Circulation       Date:  1985-07       Impact factor: 29.690

2.  Fibrinopeptide A excretion in urine: a marker of the cumulative thrombin activity in stable versus unstable angina patients.

Authors:  D Ardissino; M G Gamba; P A Merlini; A Rolla; P Barberis; G Demicheli; S Testa; N Bruno; G Specchia
Journal:  Am J Cardiol       Date:  1991-09-03       Impact factor: 2.778

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.